15 mg compounded tirzepatide Microdose Tirzepatide - 6 Month Plan

Hormonal balance matters

Pace Roland Rutschmann Merck Verona Pharma Avalyn Pharma MannKind Corporation United Therapeutics Corporation GSK Bristol Myers Squibb Endeavor BioMedicines PureTech Health Insilico Medicine Mirador Therapeutics Novo Ventures F-Prime RiverVest Venture Partners SR One Capital Management OrbiMed RA Capital Management Perceptive Advisors Wellington Management ARCH Venture Partners Surveyor Capital Foresite Capital Canaan To view or add a comment, sign in

Improved glucose control: Targeting GLP-1 and GIP receptors, retatrutide demonstrates promising results in improving insulin sensitivity and glucose regulation

Association between weight reduction achieved with tirzepatide and outcomes SURMOUNT-1

Adverse Reactions in Patients for Weight Reduction and Long-Term Maintenance Pool of Placebo-Controlled Weight Reduction Trials in Adults with Obesity or Overweight, with or without Type 2 Diabetes (Study 1 and Study 2) ZEPBOUND was evaluated for safety in a pool of two randomized, double-blind, placebo-controlled trials that included 2,519 adult patients with obesity or overweight treated with ZEPBOUND for up to 72 weeks and a 4-week off drug follow-up period (Study 1 and Study 2) [see Clinical Studies (14.1)]

Ultimately, your weight loss journey is a personal one, and your Shapely team will be by your side to help you achieve your best results Typically, we find that patients of our weight loss program in Roseville, California who are taking GLP-1 agonists such as Ozempic and Wegovy will lose 10% of weight by 6 months and 15% within 1 year